Noda T, Adachi S, Yamamoto T, Hirooka C, Kiyozuka Y, Adachi S, Oku M, Ichijo M
Dept. of Obstetrics and Gynecology, Higasiosaka Central Municipal Hospital.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1561-8.
We studied the systemic efficacy of intraperitoneal (i.p.) chemotherapy which has been used as a locoregional chemotherapy for ovarian cancer. The following results were obtained. 1) The CDDP-based i.v. and i.p. regimen obtained a 90% response rate for ascites and a 35% response rate for measurable lesions. 2) According to the pharmacokinetic analysis of i.p.-chemotherapy, BH-AC showed a regional advantage because of a high AUC-ratio. Meanwhile CDDP and etoposide demonstrated a low AUC-ratio, that has direct effects in the abdominal cavity and anti-tumor effects from the vascular side of the tumor. 3) We performed sequential i.p.-chemotherapy using three types of drainage tubes according to the stage and the size of the residual tumor at operation. The abdomino-centesis using a peel-away introducer for the poor risk patients was very easy and this method could carry out sequential CDDP-i.p.. No patients had signs or symptoms of chemical peritonitis. 4) On the base of these date, we have designed a protocol of i.p. chemotherapy for patients with ovarian cancer.
我们研究了已被用作卵巢癌局部区域化疗的腹腔内化疗的全身疗效。获得了以下结果。1）基于顺铂的静脉和腹腔内治疗方案对腹水的缓解率为90%，对可测量病变的缓解率为35%。2）根据腹腔内化疗的药代动力学分析，由于高AUC比值，BH-AC显示出区域优势。同时，顺铂和依托泊苷的AUC比值较低，它们在腹腔内有直接作用，并从肿瘤血管侧产生抗肿瘤作用。3）我们根据手术时的分期和残留肿瘤大小，使用三种类型的引流管进行序贯腹腔内化疗。对于风险较高的患者，使用可剥离导引器进行腹腔穿刺非常容易，并且这种方法可以进行序贯顺铂腹腔内化疗。没有患者出现化学性腹膜炎的体征或症状。4）基于这些数据，我们为卵巢癌患者设计了一种腹腔内化疗方案。
